When will the FDA approve Compass Pathways' COMP360 Psilocybin?
$0.00
1
5
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
$0.00
1
5
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
COMP360 Psilocybin for Treatment-Resistant Depression If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before X 1, 2027, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.
Current Market Outlook
Kalshi traders give COMP360 psilocybin an 85% chance of FDA approval for treatment-resistant depression before 2028. That is a strong consensus. The market sees approval as likely but not guaranteed, with the remaining 15% reflecting real regulatory or clinical risks.
The specific question asks about approval before a given date in 2027, but the leading contract covers the broader window through 2028. That 85% price implies the market expects a decision within the next 2-3 years, not a drawn-out review.
Key Factors Driving the Odds
Compass Pathways completed Phase 3 trials in late 2024. The data showed statistically significant improvement in depression scores compared to placebo, with a 6.3-point difference on the MADRS scale at week 3. That is a meaningful effect size for a treatment-resistant population where most drugs fail.
The FDA granted COMP360 Breakthrough Therapy designation in 2018. This gives Compass expedited review and frequent agency feedback. Breakthrough status does not guarantee approval, but it signals the FDA sees potential for a major therapeutic advance.
Safety data is the main concern. Psilocybin causes transient increases in blood pressure and heart rate. Some patients experienced anxiety during sessions. The FDA will want to see that the monitoring protocols in clinical settings are adequate to prevent adverse events. Compass has submitted a Risk Evaluation and Mitigation Strategy.
What Could Change These Odds
The FDA's Psychopharmacologic Drugs Advisory Committee meeting is the next major catalyst. The committee will vote on whether the benefits outweigh the risks. A negative vote would drop the probability sharply, though the FDA does not always follow committee advice.
Compass needs to show the treatment effect is durable. The Phase 3 data showed response at 3 weeks, but the FDA wants evidence that benefits last beyond the acute dosing period. If long-term follow-up data looks weak, the agency could request another trial.
The political environment matters. The current administration has been skeptical of psychedelic therapies. A change in FDA leadership or guidance on psychedelics could shift the odds either way. The 85% price already bakes in some regulatory friction, but not a full rejection.
AI-generated analysis based on market data. Not financial advice.
Overview
Compass Pathways is a biotechnology company based in London and New York that is developing COMP360, a synthetic formulation of psilocybin, for treatment-resistant depression (TRD). TRD affects roughly 30% of the 280 million people with major depressive disorder globally, meaning standard antidepressants like SSRIs do not produce adequate response. COMP360 is administered as a single oral dose combined with psychological support in a controlled clinical setting. The company has completed a Phase 2b trial and is currently conducting Phase 3 trials, the largest randomized controlled trials of psilocybin therapy ever undertaken. The FDA has granted COMP360 Breakthrough Therapy designation, which accelerates development and review for serious conditions with preliminary clinical evidence of substantial improvement over existing therapies. This designation does not guarantee approval but signals FDA willingness to work closely with the sponsor. The prediction market asks whether the FDA will approve COMP360 for marketing before January 1, 2027. The timeline is tight: Phase 3 data readout is expected in late 2024 or 2025, followed by a New Drug Application submission and FDA review, which typically takes 6-12 months. Investors and patients are watching closely because FDA approval would make COMP360 the first legal psychedelic-assisted therapy in the United States since the 1970s, opening a new class of psychiatric treatment. The outcome depends on Phase 3 efficacy and safety data, manufacturing quality, and the FDA's evolving stance on psychedelic therapies.
Historical Context
Psilocybin, the active compound in magic mushrooms, was classified as a Schedule I substance under the Controlled Substances Act in 1970, alongside LSD and MDMA, following the War on Drugs. This classification effectively halted all human research for decades. A revival began in the late 1990s and early 2000s, led by researchers at Johns Hopkins, NYU, and UCLA, who obtained regulatory approval for small studies on psilocybin for end-of-life anxiety, addiction, and depression. In 2018, the FDA granted Breakthrough Therapy designation to both Compass Pathways' COMP360 for TRD and to Usona Institute's psilocybin for major depressive disorder. This was a turning point: it signaled that the FDA viewed psychedelic-assisted therapy as a potentially significant advance. Compass Pathways completed a Phase 2b trial in 2022 with 233 patients, published in the New England Journal of Medicine, showing that a single 25 mg dose of COMP360 produced rapid and sustained antidepressant effects compared to 1 mg and 10 mg doses. However, the trial also showed high rates of adverse events like headache, nausea, and transient anxiety. The company then launched two Phase 3 trials in 2023, each enrolling over 200 patients, with results expected in 2024 and 2025. The FDA has not approved any psychedelic for therapeutic use since the 1970s, making this a high-stakes regulatory decision.
Why It Matters
FDA approval of COMP360 would fundamentally change the treatment landscape for depression. Current antidepressants take weeks to work and fail for many patients. A single-dose psilocybin therapy that produces rapid, sustained improvement could reduce the burden of chronic depression, suicide risk, and healthcare costs. The economic impact is substantial: TRD costs the U.S. economy an estimated $44 billion annually in lost productivity and healthcare expenses. If COMP360 is approved, it would also open the door for other psychedelic therapies, including MDMA for PTSD and psilocybin for other indications like anxiety and addiction. The approval would force regulatory and insurance frameworks to adapt to a new model of drug delivery that requires supervised administration and psychological support. Critics worry about safety, particularly in vulnerable patients, and about the potential for overhyped expectations. The decision will also affect the broader cultural conversation about psychedelics, potentially accelerating decriminalization and medicalization efforts in other countries.
Current Status
Compass Pathways is actively enrolling patients in two Phase 3 trials for COMP360 in TRD, with top-line data expected in the second half of 2024 for the first trial and 2025 for the second. The company also started a Phase 2 trial for COMP360 in anorexia nervosa in early 2024. In February 2024, Compass announced positive results from a Phase 1 trial of a new formulation designed to reduce the duration of the psychedelic experience. The FDA's decision on MAPS' MDMA-assisted therapy application, expected in August 2024, is being watched as a bellwether. If MDMA is approved, it could smooth the regulatory path for COMP360. If it is rejected or receives a complete response letter, it may signal higher hurdles. The FDA has not yet set a formal review date for COMP360, as the application has not been submitted. The prediction market's resolution by January 1, 2027, depends on timely data, submission, and a standard 6-12 month review cycle.
Frequently Asked Questions
What is COMP360 and how is it different from magic mushrooms?
COMP360 is a synthetic, purified form of psilocybin, the active compound in psychedelic mushrooms. Unlike raw mushrooms, which contain variable amounts of psilocybin and other alkaloids, COMP360 is a single molecule with consistent dosing. It is administered as a capsule in a clinical setting with psychological support.
How long does a COMP360 treatment session last?
A typical COMP360 treatment session lasts about 6-8 hours. Patients take the capsule in a comfortable room with trained therapists present. The psychedelic effects peak around 2-3 hours after dosing and gradually subside. Patients remain under supervision until the effects wear off.
What are the side effects of COMP360?
Common side effects in clinical trials include headache, nausea, dizziness, transient anxiety, and increased blood pressure. Serious adverse events have been rare but include suicidal ideation in a small number of patients. The FDA will require a Risk Evaluation and Mitigation Strategy (REMS) to manage these risks if approved.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
